Acumen Wealth Advisors LLC Has $8.72 Million Position in Johnson & Johnson $JNJ

Acumen Wealth Advisors LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.5% during the first quarter, HoldingsChannel reports. The fund owned 35,663 shares of the company’s stock after selling 4,621 shares during the period. Johnson & Johnson comprises about 2.3% of Acumen Wealth Advisors LLC’s investment portfolio, making the stock its 10th largest position. Acumen Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $8,717,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. CI Investments Inc. grew its holdings in shares of Johnson & Johnson by 83.5% during the first quarter. CI Investments Inc. now owns 317,660 shares of the company’s stock worth $77,649,000 after buying an additional 144,553 shares in the last quarter. First Trust Advisors LP lifted its stake in Johnson & Johnson by 1.6% in the 1st quarter. First Trust Advisors LP now owns 2,108,927 shares of the company’s stock valued at $515,506,000 after acquiring an additional 33,425 shares in the last quarter. Marin Bay Wealth Advisors LLC boosted its position in Johnson & Johnson by 32.1% during the 1st quarter. Marin Bay Wealth Advisors LLC now owns 3,351 shares of the company’s stock worth $819,000 after acquiring an additional 815 shares during the last quarter. Westpac Banking Corp boosted its holdings in Johnson & Johnson by 36.2% during the first quarter. Westpac Banking Corp now owns 43,274 shares of the company’s stock worth $10,578,000 after purchasing an additional 11,510 shares during the last quarter. Finally, Fortis Capital Management LLC boosted its holdings in Johnson & Johnson by 10.5% during the first quarter. Fortis Capital Management LLC now owns 6,326 shares of the company’s stock worth $1,546,000 after purchasing an additional 599 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval
• Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans
• Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article
• Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $270.00 price target on shares of Johnson & Johnson in a research note on Friday, July 17th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $263.00 to $272.00 and gave the company an “overweight” rating in a research report on Thursday, July 16th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Johnson Rice upgraded Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 price target for the company in a research note on Thursday, July 16th. Finally, Weiss Ratings lowered Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $265.30.

Johnson & Johnson Trading Up 2.0%

Shares of JNJ stock opened at $255.71 on Thursday. The company has a market capitalization of $615.56 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.38 and a beta of 0.24. The firm has a 50 day moving average price of $241.40 and a two-hundred day moving average price of $235.76. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $164.23 and a 12-month high of $269.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.68 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.